Interstitial Pneumonitis after Treatment with Pemetrexed for Non-small Cell Lung Cancer.
- Author:
Kyeong Hyun KIM
1
;
Seo Young SONG
;
Kyu Hyoung LIM
;
Seon Sook HAN
;
Se Hyun KIM
;
Jun Hwi CHO
;
Chan Woo PARK
;
Seoungkoo LEE
;
Hui Young LEE
Author Information
1. Department of Internal Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine, Chuncheon, Korea. hylee7@kangwon.ac.kr
- Publication Type:Case Report
- Keywords:
Interstitial lung diseases;
Pemetrexed;
Non-small-cell lung carcinoma;
Adenocarcinoma;
Drug therapy
- MeSH:
Adenocarcinoma;
Carcinoma, Non-Small-Cell Lung;
Cisplatin;
Disease Progression;
Glutamates;
Guanine;
Humans;
Induction Chemotherapy;
Lung Diseases, Interstitial;
Pneumonia;
Pemetrexed
- From:Cancer Research and Treatment
2013;45(1):74-77
- CountryRepublic of Korea
- Language:English
-
Abstract:
Pemetrexed is approved as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) with cisplatin and as a single agent for second-line treatment or for patients who show no disease progression after four cycles of platinum-based doublet induction chemotherapy as maintenance therapy. Pemetrexed has a modest toxicity profile and has not traditionally been regarded as a cause of interstitial pneumonitis. Here, we report on a rare case of pemetrexed-induced pneumonitis in a patient with NSCLC.
